Peptides Similar to Enlicitide Decanoate

Overview#

Enlicitide occupies a unique therapeutic niche as the first oral PCSK9 inhibitor, bridging the gap between the convenience of oral statins and the potent LDL-C lowering of injectable PCSK9 antibodies. Understanding how enlicitide compares with existing lipid-lowering therapies helps contextualize its potential clinical impact.

Injectable PCSK9 Inhibitors#

The injectable PCSK9 monoclonal antibodies are the most direct comparators to enlicitide, as they share the same pharmacological target.

Evolocumab (Repatha)#

Molecular type: Fully human IgG2 monoclonal antibody (~144 kDa)
Administration: 140 mg SC every 2 weeks or 420 mg SC monthly
LDL-C reduction: Approximately 55-60% as add-on to statin
Outcomes data: FOURIER trial demonstrated 15% reduction in major cardiovascular events
Approval: FDA approved 2015

Alirocumab (Praluent)#

Molecular type: Fully human IgG1 monoclonal antibody (~146 kDa)
Administration: 75-150 mg SC every 2 weeks
LDL-C reduction: Approximately 50-60% as add-on to statin
Outcomes data: ODYSSEY OUTCOMES trial demonstrated 15% reduction in MACE in ACS patients
Approval: FDA approved 2015

Inclisiran (Leqvio)#

Molecular type: Small interfering RNA (siRNA) targeting PCSK9 mRNA
Administration: 284 mg SC every 6 months (after initial doses)
LDL-C reduction: Approximately 50-52%
Outcomes data: ORION-4 outcomes trial ongoing
Approval: FDA approved 2021

Comparison Table#

Property	Enlicitide	Evolocumab	Alirocumab	Inclisiran
Type	Macrocyclic peptide	Monoclonal antibody	Monoclonal antibody	siRNA
Route	Oral	SC injection	SC injection	SC injection
Frequency	Once daily	Q2W or monthly	Q2W	Q6 months
MW	~1,581 Da	~144 kDa	~146 kDa	~16.3 kDa
LDL-C reduction	55-60%	55-60%	50-60%	50-52%
MACE reduction	Pending (CORALreef Outcomes)	15% (FOURIER)	15% (ODYSSEY)	Pending
Cold chain	No	Yes	Yes	Yes
Status	Phase 3	Approved	Approved	Approved

Statins#

Statins remain the first-line therapy for hypercholesterolemia. Enlicitide is positioned as add-on therapy for patients not at LDL-C goal despite maximally tolerated statin therapy.

High-Intensity Statins#

Atorvastatin 40-80 mg: LDL-C reduction approximately 50%
Rosuvastatin 20-40 mg: LDL-C reduction approximately 50-55%
Mechanism: HMG-CoA reductase inhibition (reduces cholesterol synthesis)
Note: Statins upregulate PCSK9 expression, partially offsetting their efficacy. Adding enlicitide blocks this compensatory mechanism.

Ezetimibe#

Mechanism: Inhibits cholesterol absorption at the intestinal brush border
LDL-C reduction: Approximately 15-20% as monotherapy; additive when combined with statins
Synergy with enlicitide: Ezetimibe, statins, and PCSK9 inhibition target three independent pathways of cholesterol metabolism, providing complementary LDL-C lowering

Key Differences#

Enlicitide vs Injectable PCSK9 Antibodies#

The primary differentiator is route of administration. Enlicitide delivers comparable LDL-C lowering (55-60%) through a daily oral tablet rather than biweekly/monthly injections. This addresses the key barriers to PCSK9 inhibitor adoption: injection burden, needle aversion, cold-chain logistics, and requirement for self-injection training. However, the injectable antibodies have proven cardiovascular outcomes data (FOURIER, ODYSSEY), which enlicitide currently lacks.

Enlicitide vs Inclisiran#

Inclisiran offers the advantage of twice-yearly dosing (administered by healthcare providers), addressing adherence from a different angle. However, it requires office visits for injection and has not yet demonstrated cardiovascular outcomes benefit. Enlicitide offers patient autonomy through daily self-administration with a pill.

Enlicitide vs Statins#

Statins and enlicitide are complementary rather than competitive. Statins reduce cholesterol synthesis but upregulate PCSK9 as a compensatory mechanism. Adding enlicitide blocks this PCSK9 rise, producing additive LDL-C lowering beyond what either approach achieves alone. In clinical trials, enlicitide achieved 55-60% additional LDL-C reduction on top of background statin therapy.

Enlicitide vs Bempedoic Acid#

Bempedoic acid (Nexletol) is another oral add-on to statins, reducing LDL-C by approximately 18-25%. Enlicitide produces substantially greater LDL-C lowering (55-60%), though bempedoic acid has demonstrated cardiovascular outcomes benefit in the CLEAR trial.